The Clorox Company

NYSE:CLX Aktierapport

Börsvärde: US$10.5b

Clorox Tidigare resultatutveckling

Tidigare kriterier kontrolleras 5/6

Clorox har ökat intäkterna med en genomsnittlig årlig takt på 7.4%, medan Household Products -branschen såg intäkterna växer på 1.7% årligen. Intäkterna har varit fallande med en genomsnittlig takt på 1.1% per år. Clorox s avkastning på eget kapital är 837% och den har en nettomarginal på 11.2%.

Viktig information

7.39%

Tillväxttakt i vinsten

7.89%

Tillväxttakt för EPS

Household Products Tillväxt i branschen1.51%
Intäkternas tillväxttakt-1.08%
Avkastning på eget kapital836.96%
Nettomarginal11.18%
Senaste uppdateringen av resultatet31 Mar 2026

Senaste uppdateringar av tidigare prestationer

Clorox (NYSE:CLX) Strong Profits May Be Masking Some Underlying Issues

Nov 10
Clorox (NYSE:CLX) Strong Profits May Be Masking Some Underlying Issues

Recent updates

CLX: GOJO Integration And Need Based Portfolio Focus Will Shape Future Multiple

Analysts have trimmed their average price target on Clorox by about $4 to reflect revised assumptions around long term revenue growth, profit margins, and future P/E multiples after a recent wave of target cuts and a downgrade from several major firms. Analyst Commentary The recent research flow on Clorox shows a clear shift toward more cautious price targets, even as some firms earlier in the year had raised their estimates following company updates and sector moves.

Clorox: Reduced Complexity Paves The Way For Multiple Expansion

Apr 28

CLX: Execution Risks On Growth Plans Will Restrain Future Earnings Power

Clorox's updated analyst price target holds at $94.00, with recent Street research showing a series of both increases and cuts as analysts factor in revised assumptions for revenue growth, profit margins, and future P/E expectations. Analyst Commentary Recent Street research around Clorox has shifted toward more cautious pricing, with several bearish analysts trimming their targets after reassessing revenue, margin, and P/E assumptions.

CLX: Mixed Organic Trends And GOJO Integration Will Shape Balanced Future Earnings Power

Analysts have trimmed Clorox's average price target by low double digit dollar amounts to around $94. This reflects mixed revisions across firms as they weigh softer volume expectations in consumer staples against company specific initiatives such as the GOJO acquisition and an increased focus on need based product innovation.

CLX: Need Based Product Innovation And GOJO Integration Will Support Earnings Outlook

Analysts have inched their average price targets on Clorox higher, with multiple firms lifting targets into the $120s as they factor in Clorox's plans for need based product innovation and expected benefits from the GOJO acquisition, even as some caution remains around mixed organic sales trends and broader staples sector headwinds. Analyst Commentary Recent research on Clorox reflects a split view, with several bullish analysts lifting price targets into the low to mid US$120s while a few high profile firms remain cautious with targets closer to US$90 to US$110.

CLX: Mixed Organic Trends And GOJO Integration Will Restrain Future Earnings Power

Analysts have nudged their average price target on Clorox higher by low single digits into the $120 range, citing refreshed sector targets, mixed but stable organic sales trends, and potential B2B upside from the GOJO acquisition. Analyst Commentary Recent research on Clorox has been mixed, with several firms lifting price targets into the low to mid $120s while keeping neutral or equal weight ratings.

CLX: Lingering Distribution Issues Will Cap Earnings Power And Future P/E

The analyst price target for Clorox has shifted around recent revisions, with multiple firms raising or lowering their dollar price objectives as analysts weigh updated views on long term revenue growth, profit margins, and future P/E assumptions. Analyst Commentary Recent research on Clorox shows a split tape, with several firms lifting their price targets while others are trimming expectations or keeping a more cautious stance.

CLX: Slower Distribution Recovery Will Restrain Earnings Power And Future Multiple

Analysts have reset their fair value estimate for Clorox to $94 from $115. This reflects updated assumptions for discount rates, modest revenue growth, slightly lower profit margins, and a reduced future P/E multiple, in line with recent mixed price target moves across the Street.

CLX: ERP Normalization And Volume Recovery Concerns Will Shape Multiple Re Rating

Narrative Update The updated analyst price target for Clorox has shifted slightly lower to reflect a fair value move from about $122.41 to $119.76. Analysts are factoring in recent target cuts tied to softer guidance, slower expected volume recovery, and modestly lower revenue growth, profit margin, and future P/E assumptions, partially offset by at least one small upward revision.

CLX: ERP Normalization And EPS Recovery Will Support Multiple Re Rating

Analysts have trimmed their price targets on Clorox, nudging our fair value estimate down by about $2 to $122.41 as they factor in softer Q1 results, a lower-end full-year EPS guide, and slightly more conservative assumptions for growth, margins, and future P/E. Analyst Commentary Bullish Takeaways Bullish analysts highlight that Q1 results and the full year EPS guide, while soft, were described as not as bad as feared, which they view as supportive of current valuation levels after the recent P/E reset.

CLX: Margin Recovery And ERP Progress Will Support Earnings Outlook

Clorox's analyst price target has been reduced by about $5 to reflect softer near term results and guidance, with analysts citing muted growth expectations, operating deleverage from recent disruptions, and a more cautious outlook on topline and earnings across consumer staples. Analyst Commentary Bullish analysts acknowledge that Clorox's recent results and guidance were soft, but stress that the outcome was not as negative as many investors had anticipated.

CLX: ERP Normalization And Cost Controls Will Drive Earnings Recovery

Analysts have trimmed their price targets on Clorox, collectively nudging our fair value view slightly lower, toward the Street’s new mid range around $117 to $125 per share, as they factor in softer near term results, muted growth expectations, and operating deleverage tied to service disruptions and cautious FY26 and FY27 outlooks. Analyst Commentary Analysts broadly view the latest quarter as soft but not thesis breaking, with valuation resets clustering around the low to mid $120s and embedding more modest growth and profitability assumptions.

CLX: Share Buybacks And Cost Controls Will Support Recovery Into Fiscal 2026

Analysts have reduced their average price target for Clorox by a modest amount, from approximately $124.76 to $124.59. This adjustment is due to softer recent results and tempered growth expectations reflected in the latest earnings guidance and sector trends.

Here's Why Shareholders May Want To Be Cautious With Increasing The Clorox Company's (NYSE:CLX) CEO Pay Packet

Nov 12
Here's Why Shareholders May Want To Be Cautious With Increasing The Clorox Company's (NYSE:CLX) CEO Pay Packet

Clorox (NYSE:CLX) Strong Profits May Be Masking Some Underlying Issues

Nov 10
Clorox (NYSE:CLX) Strong Profits May Be Masking Some Underlying Issues

CLX: Share Buybacks And Cost Controls Will Drive Resilience Into Fiscal 2026

Clorox's fair value price target has been lowered by analysts from $129.88 to $124.76, a change that reflects softer recent financial results and modest growth expectations, which are tempered by ongoing operational challenges. Analyst Commentary Recent analyst updates for Clorox reflect a mixed outlook, with both optimistic and cautious perspectives emerging in response to the company's latest financial results and ongoing challenges.

Analysts Lower Clorox Price Target Amid Service Disruptions and Muted Profit Outlook

Clorox's analyst price target was reduced from approximately $131.24 to $129.88, as analysts cite ongoing service disruptions, slowing sales growth, and a muted profit outlook as key factors for the adjustment. Analyst Commentary Recent research updates indicate that analysts remain cautious on Clorox shares, reflecting ongoing challenges and a muted growth outlook.

Modern ERP And Digital Marketing Will Unlock Lasting Opportunities

Clorox’s analyst price target has been lowered by approximately $2.35 per share. Analysts cite weaker revenue growth projections and ongoing operational challenges for the company.

Modern ERP And Digital Marketing Will Unlock Lasting Opportunities

Clorox’s consensus price target was revised down to $135.06 as soft consumption data, ERP-related volatility, and weak guidance have undermined near-term sales and earnings visibility. Analyst Commentary Recent soft consumption data signals weakened demand, prompting concern over short-term sales trends.

Clorox (NYSE:CLX) Has Announced That It Will Be Increasing Its Dividend To $1.24

Aug 04
Clorox (NYSE:CLX) Has Announced That It Will Be Increasing Its Dividend To $1.24

Earnings Beat: The Clorox Company Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Aug 02
Earnings Beat: The Clorox Company Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Returns On Capital At Clorox (NYSE:CLX) Have Stalled

Jul 16
Returns On Capital At Clorox (NYSE:CLX) Have Stalled

Clorox: Reviving From Cyberattack; Initiate With 'Buy'

Mar 29

Clorox: A Wonderful Business I Would Like To Own At A Lower Price

Feb 27

The Clorox Company: Hold, Trading Above Fair Value Despite Positive Signals

Nov 26

Fördelning av intäkter och kostnader

Hur Clorox tjänar och spenderar pengar. Baserat på senast rapporterade resultat, på rullande tolvmånadersbasis.

Resultat- och intäktshistorik

NYSE:CLX Intäkter, kostnader och resultat (USD Millions )
DatumIntäkterIntäkterG+A KostnaderFoU-kostnader
31 Mar 266,7607561,770116
31 Dec 256,7587551,842116
30 Sep 256,7717911,857118
30 Jun 257,1048101,896121
31 Mar 257,0196941,980122
31 Dec 247,1654572,008127
30 Sep 247,4693572,035128
30 Jun 247,0932801,985126
31 Mar 247,2092401,975132
31 Dec 237,310802,014135
30 Sep 237,035861,929136
30 Jun 237,3891491,921139
31 Mar 237,171741,837134
31 Dec 227,0654351,682130
30 Sep 227,0414051,684131
30 Jun 227,1074621,679132
31 Mar 227,1084581,711143
31 Dec 217,0802471,762144
30 Sep 217,2314371,809150
30 Jun 217,3417101,809149
31 Mar 217,5229231,813146
31 Dec 207,5241,2251,829153
30 Sep 207,1311,1511,723147
30 Jun 206,7219391,654145
31 Mar 206,3658701,557141
31 Dec 196,1338161,470136
30 Sep 196,1578131,478134
30 Jun 196,2148201,482136
31 Mar 196,2787961,458135
31 Dec 186,2447901,447133
30 Sep 186,1878411,420132
30 Jun 186,1248231,407132
31 Mar 186,0808081,427132
31 Dec 176,0407991,431135
30 Sep 176,0307161,423136
30 Jun 175,9737031,409135
31 Mar 175,9266661,432140
31 Dec 165,8756531,420140
30 Sep 165,8146541,412142
30 Jun 165,7616481,393141
31 Mar 165,7186721,348138
31 Dec 155,6936571,328137
30 Sep 155,6936341,329136
30 Jun 155,6556061,321136

Kvalitetsintäkter: CLX har inkomster av hög kvalitet.

Växande vinstmarginal: CLX s nuvarande netto vinstmarginaler (11.2%) är högre än förra året (9.9%).

Fritt kassaflöde vs resultatanalys

Analys av tidigare vinsttillväxt

Resultatutveckling: CLX s intäkter har ökat med 7.4% per år under de senaste 5 åren.

Accelererande tillväxt: CLX s intäktstillväxt under det senaste året ( 8.9% ) överstiger sitt 5-åriga genomsnitt ( 7.4% per år).

Resultat vs industri: CLX vinsttillväxt under det senaste året ( 8.9% ) översteg Household Products branschen 3%.

Avkastning på eget kapital

Hög ROE: Medan CLX s avkastning på eget kapital ( 836.96% ) är utestående, är detta mått skevt på grund av deras höga skuldnivå.

Avkastning på tillgångar

Avkastning på sysselsatt kapital

Upptäck starka bolag som tidigare presterat bra

7D

1Y

7D

1Y

7D

1Y

Företagsanalys och finansiella data Status

UppgifterSenast uppdaterad (UTC-tid)
Analys av företag2026/05/04 22:26
Aktiekurs vid dagens slut2026/05/04 00:00
Intäkter2026/03/31
Årlig intjäning2025/06/30

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

PaketUppgifterTidsramExempel US-källa
Företagets finansiella ställning10 år
  • Resultaträkning
  • Kassaflödesanalys
  • Balansräkning
Analytikernas konsensusuppskattningar+3 år
  • Prognos för finansiella poster
  • Analytikernas prismål
Marknadspriser30 år
  • Aktiekurser
  • Utdelningar, splittar och åtgärder
Ägarskap10 år
  • Största aktieägare
  • Insiderhandel
Förvaltning10 år
  • Ledningsgrupp
  • Styrelse och verkställande direktörer
Viktiga utvecklingstendenser10 år
  • Företagsmeddelanden

* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

The Clorox Company bevakas av 35 analytiker. 12 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

AnalytikerInstitution
John StaszakArgus Research Company
Lauren LiebermanBarclays
Lauren LiebermanBarclays